Creyon Bio engineers oligonucleotide-based medicines (OBMs) using machine learning models and custom data sets to create precise gene-centric therapies with minimal off-target effects. This approach enables the rapid development of safe and effective treatments for both rare and common diseases, significantly reducing costs and time to market.
Funding
$45.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DBFounders
Product
Problem
Traditional drug development for both rare and common diseases is often slow and costly, with challenges in achieving precise targeting and minimizing off-target effects. This can lead to prolonged development timelines and increased expenses, hindering the availability of effective treatments.
Solution
Creyon Bio is engineering oligonucleotide-based medicines (OBMs) through the use of machine learning models and custom datasets to create precise, gene-centric therapies. This approach aims to minimize off-target effects and accelerate the development of safe and effective treatments. By leveraging purpose-built data and machine learning, Creyon Bio intends to streamline the drug development process, reduce costs, and improve the predictability of efficacy and safety profiles for new medicines. The company's modular approach is designed to address diseases impacting both small and large patient populations.
Target Audience
Creyon Bio's primary focus is on developing treatments for patients with both rare and common diseases, as well as partnering with industry, patient advocates, and policymakers to accelerate drug development.
Features
- Development of oligonucleotide-based medicines (OBMs)
- Utilization of machine learning models for precise targeting
- Custom datasets designed to drive efficient model creation
- Focus on minimizing off-target effects in gene-centric therapies
- Modular approach to drug development for rapid iteration